Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | GAA | P10253 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | HPGD | P15428 | 3/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | GLA | P06280 | 1/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | HTR3A | P46098 | 6/20 | 0.62 |
| ▸ | CACNA1G | O43497 | 3/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2118623 | 0.91 | ALDH1A1 (0.69) | MAPTKMT2AGAAALDH1A1HPGD | |
| SCHEMBL4253579 | 0.90 | GAA (0.65) | MAPTKMT2AGAAALDH1A1HPGD | |
| SCHEMBL4256455 | 0.90 | GAA (0.72) | MAPTKMT2AGAAALDH1A1HPGD | |
| SCHEMBL6301538 | 0.87 | GAA (0.62) | MAPTKMT2AGAAALDH1A1HPGD | |
| SCHEMBL4249018 | 0.86 | HTR3A (0.63) | MAPTKMT2AGAAALDH1A1HPGD | |
| SCHEMBL7194154 | 0.85 | HPGD (0.59) | MAPTKMT2AGAAALDH1A1HPGD | |
| SCHEMBL4249457 | 0.84 | SMN1; SMN2 (0.67) | MAPTKMT2AGAAALDH1A1HPGD | |
| SCHEMBL4253715 | 0.84 | HTR3A (0.67) | MAPTKMT2AGAAALDH1A1HPGD | |
| SCHEMBL4258648 | 0.84 | GAA (0.63) | MAPTKMT2AGAAALDH1A1HPGD | |
| SCHEMBL6306378 | 0.83 | KMT2A (0.77) | MAPTKMT2AGAAALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748422-B2 | Pharmaceutical compositions containing quinazoline derivatives for treating as serotonin receptor antagonist | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2014-06-10 | — | — | US | disclosed |
| US-20090054433-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING QUINAZOLINE DERIVATIVES FOR TREATING AS SEROTONIN RECEPTOR ANTAGONIST | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054433-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING QUINAZOLINE DERIVATIVES FOR TREATING AS SEROTONIN RECEPTOR ANTAGONIST | HTR3A, HTR3B, HTR3E | MAPT 400/4885KMT2A 1077/4885GAA 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.